vs
Side-by-side financial comparison of B&G Foods, Inc. (BGS) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
B&G Foods, Inc. is the larger business by last-quarter revenue ($439.3M vs $281.3M, roughly 1.6× Guardant Health, Inc.). B&G Foods, Inc. runs the higher net margin — -4.4% vs -45.7%, a 41.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -4.7%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-70.7M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -12.8%).
B&G Foods, Inc. is an American branded foods holding company based in Parsippany, New Jersey. The company was formed in 1996 to acquire Bloch & Guggenheimer, a Manhattan-based producer of pickles, relish and condiments which had been founded in 1889.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
BGS vs GH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $439.3M | $281.3M |
| Net Profit | $-19.1M | $-128.5M |
| Gross Margin | 22.5% | 64.6% |
| Operating Margin | 2.5% | -43.0% |
| Net Margin | -4.4% | -45.7% |
| Revenue YoY | -4.7% | 39.4% |
| Net Profit YoY | -356.5% | -15.8% |
| EPS (diluted) | $-0.24 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $281.3M | ||
| Q3 25 | $439.3M | $265.2M | ||
| Q2 25 | $424.4M | $232.1M | ||
| Q1 25 | $425.4M | $203.5M | ||
| Q4 24 | $551.6M | $201.8M | ||
| Q3 24 | $461.1M | $191.5M | ||
| Q2 24 | $444.6M | $177.2M | ||
| Q1 24 | $475.2M | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $-19.1M | $-92.7M | ||
| Q2 25 | $-9.8M | $-99.9M | ||
| Q1 25 | $835.0K | $-95.2M | ||
| Q4 24 | $-222.4M | $-111.0M | ||
| Q3 24 | $7.5M | $-107.8M | ||
| Q2 24 | $3.9M | $-102.6M | ||
| Q1 24 | $-40.2M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | 22.5% | 64.7% | ||
| Q2 25 | 20.5% | 65.0% | ||
| Q1 25 | 21.2% | 63.3% | ||
| Q4 24 | 21.5% | 61.6% | ||
| Q3 24 | 22.2% | 61.1% | ||
| Q2 24 | 20.7% | 59.1% | ||
| Q1 24 | 22.9% | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | 2.5% | -37.3% | ||
| Q2 25 | 5.2% | -45.9% | ||
| Q1 25 | 8.4% | -54.6% | ||
| Q4 24 | -46.6% | -62.4% | ||
| Q3 24 | 11.1% | -61.3% | ||
| Q2 24 | 9.9% | -56.8% | ||
| Q1 24 | -3.3% | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | -4.4% | -35.0% | ||
| Q2 25 | -2.3% | -43.0% | ||
| Q1 25 | 0.2% | -46.8% | ||
| Q4 24 | -40.3% | -55.0% | ||
| Q3 24 | 1.6% | -56.3% | ||
| Q2 24 | 0.9% | -57.9% | ||
| Q1 24 | -8.5% | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $-0.24 | $-0.74 | ||
| Q2 25 | $-0.12 | $-0.80 | ||
| Q1 25 | $0.01 | $-0.77 | ||
| Q4 24 | $-2.81 | $-0.90 | ||
| Q3 24 | $0.09 | $-0.88 | ||
| Q2 24 | $0.05 | $-0.84 | ||
| Q1 24 | $-0.51 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.9M | $378.2M |
| Total DebtLower is stronger | $2.0B | $1.5B |
| Stockholders' EquityBook value | $470.7M | $-99.3M |
| Total Assets | $2.9B | $2.0B |
| Debt / EquityLower = less leverage | 4.30× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | $60.9M | $580.0M | ||
| Q2 25 | $54.1M | $629.1M | ||
| Q1 25 | $61.2M | $698.6M | ||
| Q4 24 | $50.6M | $525.5M | ||
| Q3 24 | $54.7M | $585.0M | ||
| Q2 24 | $40.3M | $933.7M | ||
| Q1 24 | $42.5M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $2.0B | $1.1B | ||
| Q2 25 | $2.0B | $1.1B | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $2.0B | $1.1B | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | — | $-99.3M | ||
| Q3 25 | $470.7M | $-354.5M | ||
| Q2 25 | $501.4M | $-305.5M | ||
| Q1 25 | $513.1M | $-250.8M | ||
| Q4 24 | $524.8M | $-139.6M | ||
| Q3 24 | $755.3M | $-60.1M | ||
| Q2 24 | $765.0M | $-1.6M | ||
| Q1 24 | $781.2M | $68.3M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $2.9B | $1.3B | ||
| Q2 25 | $2.9B | $1.3B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $3.4B | $1.5B | ||
| Q2 24 | $3.4B | $1.6B | ||
| Q1 24 | $3.4B | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | 4.30× | — | ||
| Q2 25 | 3.97× | — | ||
| Q1 25 | 3.91× | — | ||
| Q4 24 | 3.85× | — | ||
| Q3 24 | 2.75× | — | ||
| Q2 24 | 2.67× | — | ||
| Q1 24 | 2.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-64.6M | $-26.4M |
| Free Cash FlowOCF − Capex | $-70.7M | $-54.2M |
| FCF MarginFCF / Revenue | -16.1% | -19.3% |
| Capex IntensityCapex / Revenue | 1.4% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $54.8M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.4M | ||
| Q3 25 | $-64.6M | $-35.4M | ||
| Q2 25 | $17.8M | $-60.3M | ||
| Q1 25 | $52.7M | $-62.7M | ||
| Q4 24 | $80.3M | $-64.5M | ||
| Q3 24 | $4.2M | $-51.1M | ||
| Q2 24 | $11.3M | $-94.0M | ||
| Q1 24 | $35.1M | $-30.3M |
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $-70.7M | $-45.8M | ||
| Q2 25 | $11.5M | $-65.9M | ||
| Q1 25 | $42.4M | $-67.1M | ||
| Q4 24 | $71.7M | $-83.4M | ||
| Q3 24 | $-679.0K | $-55.3M | ||
| Q2 24 | $5.2M | $-99.1M | ||
| Q1 24 | $27.5M | $-37.2M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | -16.1% | -17.3% | ||
| Q2 25 | 2.7% | -28.4% | ||
| Q1 25 | 10.0% | -33.0% | ||
| Q4 24 | 13.0% | -41.3% | ||
| Q3 24 | -0.1% | -28.9% | ||
| Q2 24 | 1.2% | -55.9% | ||
| Q1 24 | 5.8% | -22.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | 1.4% | 3.9% | ||
| Q2 25 | 1.5% | 2.4% | ||
| Q1 25 | 2.4% | 2.2% | ||
| Q4 24 | 1.6% | 9.4% | ||
| Q3 24 | 1.0% | 2.2% | ||
| Q2 24 | 1.4% | 2.9% | ||
| Q1 24 | 1.6% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 63.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 2.87× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGS
| Specialty Segment | $150.5M | 34% |
| Meals Segment | $110.0M | 25% |
| Spices And Flavor Solutions Segment | $101.4M | 23% |
| Frozen And Vegetables Segment | $77.4M | 18% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
